Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 4/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.65 |
| ▸ | PLK4 | O00444 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409829 | 0.82 | RAD52 (0.62) | WEE1ALKMITFRAD52JAK2 | |
| SCHEMBL28942655 | 0.79 | EGFR (0.80) | WEE1ALKPLK4EGFRJAK2 | |
| SCHEMBL30138099 | 0.79 | EGFR (0.80) | WEE1ALKPLK4EGFRJAK2 | |
| SCHEMBL23906242 | 0.78 | WEE1 (0.57) | WEE1ALKPLK4MITFRAD52 | |
| SCHEMBL30086722 | 0.78 | WEE1 (0.57) | WEE1ALKPLK4MITFRAD52 | |
| SCHEMBL28202825 | 0.78 | KDM1A (0.56) | WEE1ALKPLK4MITFRAD52 | |
| SCHEMBL14660127 | 0.78 | CD274 (0.57) | WEE1ALKMITFRAD52EGFR | |
| SCHEMBL4382690 | 0.77 | JAK2 (0.58) | WEE1ALKRAD52EGFRJAK2 | |
| SCHEMBL374566 | 0.77 | CDK9 (0.53) | WEE1ALKMITFRAD52JAK2 | |
| SCHEMBL30138095 | 0.76 | WEE1 (0.69) | WEE1ALKPLK4EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | WEE1 1860/4885ALK 133/4885PLK4 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.